RUNX3 was well identified to function as a tumour suppressor, and its inactivation was associated with tumorigenesis in lung adenocarcinoma, intestinal adenocarcinoma, colorectal cancer and gastric cancer.12, 13, 14, 15. Here, RUNX3 is linked to gastric cancer.